BioNTech Sets Date for 2025 Financial Results Release

BioNTech will report its full-year 2025 financial results on March 10, 2026, with a key focus on its strategic pivot to oncology and its impact on the company's financial performance.

Investors in BioNTech SE now have a key date to mark on their calendars. The German biotechnology firm has officially scheduled the release of its full-year and fourth-quarter 2025 financial results. The announcement, set for Tuesday, March 10, 2026, will be followed by a management conference call to discuss the figures and provide a strategic update.

The upcoming report arrives at a pivotal moment for the Mainz-based company. As BioNTech increasingly shifts its strategic emphasis toward oncology research, the market is keenly awaiting financial data that reflects progress in this new chapter. The balance sheet will offer crucial evidence of how the company's evolving focus is translating into its financial performance.

Strategic Pivot Under Scrutiny

Market observers are expected to pay particularly close attention to developments within BioNTech's oncology pipeline, which is viewed as the central future growth driver. The accompanying corporate update from management will therefore be critical for contextualizing development priorities and the outlook for the year ahead. This conference call is scheduled to begin at 1:00 p.m. Central European Time (8:00 a.m. Eastern Time).

Recent trading activity has seen the company's shares exhibit a muted response to broader market movements. The stock is currently trading around €94, representing a decline of nearly 16% year-to-date. The forthcoming financial disclosure may provide fresh momentum and a new basis for evaluating this performance trajectory.

For shareholders, March 10 stands as the next significant milestone. Interested parties can listen to a live webcast of the presentation via the BioNTech investor relations website. A recording will also be made available on the same site for a period of 30 days following the event.